Epistemis

Salmeterol, Formoterol, Indacaterol, Olodaterol and Vilanterol

  • $\beta_2$-Adrenergic Agonists with Prolonged and Ultra-Prolonged Action

LABA (long-acting, 12 hours) and Ultra-LABA (ultra-long-acting, 24 hours) form the basis of maintenance bronchodilator treatment. Its structural modifications determine its lipid solubility, onset speed and affinity for the receptor.

Mechanism

Chemistry of molecular persistence

The persistence of the bronchodilator effect depends on the physical interaction of the drug with the membrane and the receptor microenvironment:

  • Salmeterol (Extreme Lipophilic): It has a long aliphatic side chain that anchors non-covalently in a hydrophobic cleft of the receptor (exo-site). This allows the active head of the molecule to oscillate and dock repeatedly to the active site, conferring a duration of action >12 hours but with a slow onset (>15 minutes).
  • Formoterol (Moderate lipophilic): It dissolves in the lipid bilayer of the bronchial cell membrane, which acts as a sustained release reservoir towards the receptor. It combines an onset of action as rapid as that of salbutamol (1 - 3 minutes) with a long duration (12 hours).
  • Ultra-LABAs (Indacaterol, Olodaterol, Vilanterol): Designed with high intrinsic affinity for the lipid domains of the cell membrane and an extremely slow dissociation rate from the β2 receptor, which prolongs the biological half-life and allows a single daily dosing of 24 hours.

Pharmacokinetics

Comparative pharmacokinetics

Drug Start of Action Duration of Effect Metabolic Clearance Half-life (t1/2)
Salmeterol 15 - 20 minutes ~12 hours Extensive hepatic by CYP3A4 to mild active metabolites ~5.5 hours
Formoterol 1 - 3 minutes ~12 hours Hepatic by direct glucuronidation (UGT) and CYP2C19 ~10 hours
Indacaterol 5 minutes >24 hours Hepatic via CYP3A4 and conjugation; excellent tissue retention ~40 - 52 hours
Olodaterol 5 minutes >24 hours Hepatic by glucuronidation and subsequent O-demethylation ~45 hours
Vilanterol 5 minutes >24 hours Extensive hepatic pathway CYP3A4 to inactive metabolites ~16 - 21 hours

Indicators and dose

Approved clinical indications

  • COPD: Maintenance bronchodilator treatment to control dyspnea and prevent exacerbations (LABA alone or combined with LAMA/ICS).
  • Bronchial Asthma: Maintenance and control treatment, only in fixed combination with an inhaled corticosteroid (ICS), from step 3 of the GINA guideline.

Dosage and Clinical Adjustment

Adults:

  • Salmeterol (50 µg): 1 inhalation every 12 hours (DPI or pMDI).
  • Formoterol (4.5 - 9 µg or 12 µg): 1 or 2 inhalations every 12 hours. Formoterol is used in the SMART (maintenance and relief) regimen associated with budesonide.
  • Indacaterol (150 µg in COPD): 1 inhalation once a day using a Breezhaler inhaler.
  • Vilanterol (22 µg): In fixed combinations (with fluticasone or umeclidinium) once a day.

Clinical Adjustments: As with SABAs, no dose adjustment is required in patients with renal or hepatic impairment with usual inhaled doses.

Security

Asthma Safety Alert: The Danger of Monotherapy (Black Box)

LABAs should never be prescribed as monotherapy in the treatment of asthma. Large clinical trials (such as the SMART study) demonstrated that LABA monotherapy significantly increases the risk of severe exacerbations and asthma-related deaths. This is because persistent bronchodilation masks the underlying airway inflammation, which continues to progress subclinically. In asthma, LABAs should always be associated with an inhaled corticosteroid (ICS). In COPD, LABA monotherapy is safe and accepted.

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

PreviousSalbutamol and Terbutaline
System
Respiratory
Cluster
$\beta_2$-Adrenergic Agonists with Prolonged and…
Download Epistemis